HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $20 to $21.
Jaguar Health Announces FDA Activation Of Third-Party Investigational New Drug Application For Evaluation Of Crofelemer For Treatment Of Uncontrolled Diarrhea In Patient With Short Bowel Syndrome
Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated IND
SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2023 / Jaguar Health (NASDAQ:JAGX) ("the
